How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/abt-335.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

ABT-335 — Competitive Intelligence Brief

ABT-335 (ABT-335) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PPARδ agonist. Area: Cardiovascular.

phase 3 PPARδ agonist PPARδ (peroxisome proliferator-activated receptor delta) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

ABT-335 (ABT-335) — AstraZeneca. ABT-335 is a selective peroxisome proliferator-activated receptor delta (PPARδ) agonist that modulates lipid and glucose metabolism.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
ABT-335 TARGET	ABT-335	AstraZeneca	phase 3	PPARδ agonist	PPARδ (peroxisome proliferator-activated receptor delta)
DA-6034	DA-6034	Dong-A ST Co., Ltd.	phase 3	PPARδ agonist	PPARδ (peroxisome proliferator-activated receptor delta)
TRC150094	TRC150094	Torrent Pharmaceuticals Limited	phase 3	PPARδ agonist	PPARδ (Peroxisome proliferator-activated receptor delta)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PPARδ agonist class)

AstraZeneca · 1 drug in this class
Dong-A ST Co., Ltd. · 1 drug in this class
Torrent Pharmaceuticals Limited · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ABT-335 — Competitive Intelligence Brief. https://druglandscape.com/ci/abt-335. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab